Back

Clinical Case Discussion

Clinical Case Discussion: Mycotic Aortic Aneurysm and Psoas Abscess as a Complication of Bacillus Calmette-Guérin Instillations

By: A.C. Witjens and J.A. Witjes

EU Focus, Volume 2 Issue 4, October 2016, Pages 353-354

Published online: 01 October 2016

Abstract Full Text Full Text PDF (94 KB)

Take Home Message

After an infectious complication caused by bacillus Calmette-Guérin (BCG), consider a dose reduction. Treatment of a mycotic aneurysm with an endostent seems safe; however, continuation of BCG after mycotic aneurysm treatment is not advised.

1. Case details

This case report describes a man aged 60 yr with multiple pT1 grade 3 bladder tumours. With this pathology, there is an indication for bacillus Calmette-Guérin (BCG) instillations to reduce recurrence. During the instillations, this patient presented with malaise and back pain, which appeared to be a mycotic aneurysm of the abdominal aorta. After 6 mo, BCG was continued, and this was followed again by malaise, night sweating, and back pain. Positron emission tomography and computed tomography (CT) showed a psoas abscess.

Mycotic aneurysm is a serious complication of intravesical BCG instillation. Fortunately, this complication is not common. In the case report, after reconstruction of the aneurysm with an endostent, there was a second complication: a psoas abscess. Should BCG be continued in this case? Is prophylactic treatment necessary? And what is the best way to repair the aneurysm at that moment? We tried to answer these important questions.

2. Discussion

As discussed in the case report, 20 cases of mycotic abdominal aortic aneurysm as a complication of BCG have been reported in the literature. In addition, a few cases of mycotic aneurysm of the thoracic aorta [1] and femoral [2], carotid [3], and popliteal [4] arteries have been described. Consequently, when vascular screening before starting BCG is considered, all of the large arteries should be considered. Although the exact incidence of mycotic aneurysm after BCG is not known, and despite the fact that a mycotic aneurysm can be life-threatening, it seems that the incidence is so low that screening is not likely to be a cost-effective procedure.

In the work-up for haematuria, at least an ultrasound will be performed in which abdominal aneurysms can be detected. Guidelines even advise CT urography or intravenous urography at the time of diagnosis of non–muscle-invasive bladder cancer (NMIBC) in selected cases, such as those with multiple- or high-risk tumours. Preexisting abdominal aneurysm will be diagnosed by CT.

Intravesical BCG therapy has an important role in the treatment of NMIBC to reduce the risk of progression or recurrence. There are many BCG schedules, most of which start with a weekly induction schedule for 6 wk. The case report mentioned a re-resection after three instillations and then a weekly BCG schedule for 6 wk. After the second of three instillations, the contained rupture of the abdominal aorta was diagnosed and an endostent was placed. About 5 mo later, weekly BCG maintenance continued for 3 wk. After this session, an infectious complication occurred again and BCG was stopped. After the introduction schedule of six instillations, a maintenance schedule is recommended for the prevention of recurrence or progression [5]. There is no consensus about the exact maintenance schedule, so caution is wise when a serious complication has already occurred, for example, by giving only two or three BCG instillations after the initial six instillations or perhaps by dose reduction.

Reducing the dose does not seem useful according to the results of a European Organisation for Research and Treatment of Cancer (EORTC) study group; there was no difference in toxicity between one-third and full-dose BCG, but the one-third dose of BCG was associated with a higher recurrence rate, especially when given for only 1 yr [6] and [7]. In contrast, other studies showed that a half-dose BCG instillation resulted in fewer side effects, without differences in recurrence or progression [8]. A meta-analysis even reported a 48% lower risk of severe side effects for low-dose BCG [9]. Although none of these reports mentioned a systemic BCG infection, as in this case report, perhaps a dose reduction in this case would have been appropriate, considering the many BCG side effects from the start.

Tuberculostatic agents, such as isoniazid, are used to diminish or treat the local irritative symptoms and systemic side effects caused by intravesical BCG. Another EORTC study showed that prophylactic administration of isoniazid during BCG instillations provides no decrease in any known side effect of BCG [10]. Alternatively, Colombel et al. showed a decrease in incidence of moderate and severe adverse events during BCG with ofloxacin [11]; however, there were no complications such as infectious aneurysms, so whether early preventive therapy would have made sense in this case remains questionable.

Treatment of an infectious aneurysm with an endostent is questionable. The major concern is persistent infection or reinfection of the graft. Muller et al. described repair of 33 mycotic aneurysms of thoracic and abdominal aortas and iliac arteries. In situ repair with patch plasty or tube graft does not seem to be related to higher morbidity or mortality compared with revascularisation with extra-anatomic procedures [12]. More case reports are available in which endovascular grafting was a successful treatment of infected abdominal aortic aneurysm [13]. According to vascular surgeons, the indications for endograft repair of infected aneurysms have remained inconclusive (pers. comm.). Nevertheless, based on the little available evidence, an endostent is an option. In these cases, if cultures are positive for Mycobacterium bovis, long-term treatment with antituberculous therapy is advisable.

Continuing BCG after an endostent depends on multiple factors: the pathology results of the initial bladder tumour, the number of instillations already given, the results of blood culture and CT scan after the endostent procedure, and the condition of the patient. We feel, however, that reintroduction of BCG would seem one step too far after a proven systemic BCG infection, as in this case.

3. Treatment strategy

After an infectious complication caused by BCG, consider a dose reduction. It is unlikely that isoniazid prophylaxis prevents infectious complications such as those in this case. Treatment of a mycotic aneurysm with an endostent seems safe, based on the little available evidence; however, continuation of BCG after mycotic aneurysm treatment is not advised.

Conflicts of interest

The authors have nothing to disclose.

References

  • [1] D.S. Hui, D.A. Stoeckel, E.E. Kaufman, D.L. Jacobs. Massive hemoptysis from an aortobronchial fistula secondary to BCG-related mycotic thoracic aortic aneurysm. Ann Thorac Surg. 2016;101:350-352
  • [2] C.T. Costiniuk, A.A. Sharapov, G.W. Rose, et al. Mycobacterium bovis abdominal aortic and femoral artery aneurysms following intravesical bacillus Calmette–Guérin therapy for bladder cancer. Cardiovasc Pathol. 2010;19:E29-E32 Crossref
  • [3] R. Coscas, J.-B. Arlet, D. Belhomme, J.-N. Fabiani, J. Pouchot. Multiple mycotic aneurysms due to Mycobacterium bovis after intravesical bacillus Calmette-Guérin therapy. J Vasc Surg. 2009;50:1185-1190 Crossref
  • [4] J.A. Witjes, J.L.J. Vriesema, K. Brinkman, G. Bootsma, J.O. Barentsz. Mycotic aneurysm of the popliteal artery as a complication of intravesical BCG therapy for superficial bladder cancer. Case report and literature review. Urol Int. 2003;71:430-432 Crossref
  • [5] A. Böhle, P.R. Bock. Intravesical bacillus Calmette-Guerin versus mitomycin C in superficial bladder cancer: formal meta-analysis of comparative studies on tumour progression. Urology. 2004;63:682-686
  • [6] M. Brausi, J. Oddens, R. Sylvester, et al. Side effects of bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC Genito-Urinary Cancers Group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014;65:69-76 Crossref
  • [7] J. Oddens, M. Brausi, R. Sylvester, et al. Final results of an EORTC-GU Cancers Group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol. 2013;63:462-472 Crossref
  • [8] A. Yokomizo, Y. Kanimoto, T. Okamura, et al. Randomized controlled study of the efficacy, safety and quality of life with low dose bacillus Calmette-Guerin instillation therapy for nonmuscle invasive bladder cancer. J Urol. 2016;195:41-46
  • [9] S. Zeng, X. Yu, C. Ma, et al. Low-dose versus standard dose of bacillus Calmette-Guerin in the treatment of nonmuscle invasive bladder cancer: a systematic review and meta-snalysis. Medicine. 2015;94:e2176
  • [10] P.D. Vegt, A.P. van der Meijden, R. Sylvester, M. Brausi, W. Höltl, C. de Balincourt. Does isoniazid reduce side effects of intravesical bacillus Calmette-Guerin therapy in superficial bladder cancer? Interim results of European Organization for Research and Treatment of Cancer protocol 30911. J Urol. 1997;157:1246-1249
  • [11] M. Colombel, F. Saint, D. Chopin, B. Malavaud, L. Nicolas, P. Rischmann, ITB01 Study Group. The effect of ofloxacin on bacillus Calmette-Guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study. J Urol. 2006;176:935-939 Crossref
  • [12] B.T. Muller, O.R. Wegener, K. Grabitz. Mycotic aneurysms of the thoracic and abdominal aorta and iliac arteries: experience with anatomic and extra-anatomic repair in 33 cases. J Vasc Surg. 2001;33:106-113 Crossref
  • [13] C. Berchtold, C. Eibl, M.H. Seelig. Endovascular treatment and complete regression of an infected abdominal aortic aneurysm. J Endovasc Ther. 2002;9:543-548

Footnotes

Department of Urology, Radboud University Medical Centre, Nijmegen, The Netherlands

Corresponding author. Department of Urology, Radboud University Medical Centre, Geert Grooteplein Zuid 10, Nijmegen, 6525GA, The Netherlands. Tel. +31 00614657323.

Place a comment

Your comment *

max length: 5000